Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Induction chemotherapy followed by chemoradiotherapy preoperative cisplatin, 5FU and panitumumab in the treatment of advanced oeso-gastric cancer and operable [Chimiotherapie d'induction suivie d'une radiochimiotherapie preoperatoire a base de cisplatine, 5FU et panitumumab dans le traitement des cancers oesogastriques avances et operables]

Trial Profile

Induction chemotherapy followed by chemoradiotherapy preoperative cisplatin, 5FU and panitumumab in the treatment of advanced oeso-gastric cancer and operable [Chimiotherapie d'induction suivie d'une radiochimiotherapie preoperatoire a base de cisplatine, 5FU et panitumumab dans le traitement des cancers oesogastriques avances et operables]

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top